STOCK TITAN

Vanguard realigns reporting; no beneficial stake in Rezolute (RZLT)

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G/A

Rhea-AI Filing Summary

The Vanguard Group amended its Schedule 13G reporting for Rezolute Inc., stating it beneficially owns 0 shares of common stock, representing 0% of the class as disclosed in the filing. The amendment explains an internal realignment and separate reporting by subsidiaries effective January 12, 2026.

Positive

  • None.

Negative

  • None.

Insights

Amendment documents disaggregation of reporting following Vanguard's internal realignment.

The filing states that, following an internal realignment on January 12, 2026, certain Vanguard subsidiaries will report beneficial ownership separately in reliance on SEC Release No. 34-39538.

This amendment records 0 shares beneficially owned and reassigns reporting responsibilities; cash‑flow treatment and any holdings by subsidiaries are not described in this excerpt.

Disclosure confirms no Vanguard beneficial ownership in Rezolute common stock per this amendment.

The filing explicitly lists "Amount beneficially owned: 0" and "Percent of class: 0 %," which indicates Vanguard does not report a beneficial stake here.

Examples of subsidiary disaggregation are noted; subsequent filings by those subsidiaries may show different holdings if applicable.






Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)




schemaVersion:


SCHEDULE 13G




Comment for Type of Reporting Person: On January 12, 2026, The Vanguard Group, Inc. went through an internal realignment. In accordance with SEC Release No. 34-39538 (January 12, 1998), certain subsidiaries or business divisions of subsidiaries of The Vanguard Group, Inc., that formerly had, or were deemed to have, beneficial ownership with The Vanguard Group, Inc., will report beneficial ownership separately (on a disaggregated basis) from The Vanguard Group, Inc. in reliance on such release. These subsidiaries and/or business divisions pursue the same investment strategies as previously pursued by The Vanguard Group, Inc. prior to the realignment. Further in accordance with SEC Release No. 34-39538 (January 12, 1998), The Vanguard Group, Inc. no longer has, or is deemed to have, beneficial ownership over securities beneficially owned by such subsidiaries and/or business divisions.


SCHEDULE 13G



The Vanguard Group
Signature:Ashley Grim
Name/Title:Head of Global Fund Administration
Date:03/26/2026

FAQ

What does the Schedule 13G/A say about Rezolute Inc (RZLT) ownership?

It states that The Vanguard Group beneficially owns 0 shares, representing 0% of Rezolute's common stock. The amendment explains Vanguard's internal realignment on January 12, 2026, after which certain subsidiaries report ownership separately.

Does this filing mean Vanguard sold Rezolute (RZLT) shares?

No, the filing does not state a sale; it records beneficial ownership as 0 shares and 0%. The amendment attributes reporting changes to an internal realignment rather than a disclosed sale transaction.

Will other Vanguard entities now report any Rezolute (RZLT) holdings?

The amendment states certain subsidiaries or business divisions will report separately in reliance on SEC Release No. 34-39538. It does not list any subsidiary holdings in this excerpt; subsequent filings would show any such holdings.

Who signed the Schedule 13G/A amendment for Rezolute (RZLT)?

The filing is signed by Ashley Grim, Head of Global Fund Administration, with the signature date shown as 03/26/2026. The signature certifies the amended disclosure details provided in the form.

What is the practical impact of this Schedule 13G/A on Rezolute (RZLT) investors?

The amendment reports Vanguard's beneficial ownership as 0 shares (0%), which is an administrative disclosure item. It does not change Rezolute's capital structure or state any transactions in this excerpt.
Rezolute Inc

NASDAQ:RZLT

View RZLT Stock Overview

RZLT Rankings

RZLT Latest News

RZLT Latest SEC Filings

RZLT Stock Data

311.02M
85.88M
Biotechnology
Pharmaceutical Preparations
Link
United States
REDWOOD CITY